-
AAX Biotech teams up with Austrian AI player on cancer antibodies
AAX Biotech is entering into a research collaboration with Austrian company Discovery Evolution. The companies will combine their technologies to develop new antibody candidates for cancer treatment.
-
Boehringer doubles down on China with $7.4 billion deal
Boehringer Ingelheim continues to strengthen its ties with China’s growing pharmaceutical industry. The German pharmaceutical giant has now signed an agreement with Sino Biopharmaceutical covering six cancer programmes, with a potential value of nearly $7.4 billion.
-
Updated: Egetis receives SEK 5.3 billion takeover bid from US company
US-based ANI Pharmaceuticals has made a SEK 5.3 billion takeover bid for Swedish Egetis Therapeutics. Chairman Mats Blom tells Life Science Focus why the board decided to consider a sale, despite the company's ambitions to grow independently.
-
Cyberattack hits French blood service
A cyberattack overnight on Sunday led to a sharp rise in temperature settings in refrigerators storing donated blood at France’s national blood service, Établissement français du sang (EFS).
-
Egetis sells FDA voucher for 190 million dollars
Swedish biotech Egetis Therapeutics is selling the priority review voucher it recently received following the U.S. approval of its drug Emcitate. The price tag is USD 190 million, half of which will go to the company.
-
Five doctors charged in Swedish prescription fraud scheme
Thirteen people, including five doctors, have been charged in a multi-million-krona fraud scheme in which a drug used to treat excessive sweating is suspected of having been prescribed without medical justification.
-
Eli Lilly drops Alzheimer’s drug candidate after phase II trial
Eli Lilly is discontinuing development of its Alzheimer’s drug candidate mevidalen. The decision follows a phase II trial that failed to meet the company’s expectations – even as the pharmaceutical giant invests billions to strengthen its neurology portfolio.
-
SynAct Pharma signs first dengue drug deal
SynAct Pharma has entered into its first commercial partnership for resomelagon as a potential treatment for dengue fever.
-
J&J hails early prostate cancer data as “the best we have ever seen”
A new prostate cancer pill achieved a tumour response in 75 per cent of patients whose tumours could be measured in a phase I study.
-
Lilly’s obesity ads on the underground cleared by watchdog
Eli Lilly’s advertising campaign about obesity did not breach industry rules on advertising aimed at the general public, according to a ruling by the Swedish pharmaceutical industry’s Information Examination Board (IGN).
-
”Cybersecurity Is Patient Safety”
Avivit Kotler, Chief Information Security and Data Protection Officer at Clalit Health Services in Israel will participate in the MVA Annual Summit 2026 November 2nd in Copenhagen. Kotler will share key insights regarding the cybersecurity threats facing Western healthcare systems. She will also discuss Israel’s experience in combating the threats its own healthcare system has recently faced.
-
Roche doubles down on Chinese biotech in deal worth up to $15 billion
A year after their first antibody-drug conjugate deal, Roche and China’s Hansoh Pharmaceutical are expanding their partnership. The new agreement covers several cancer programmes and could bring Hansoh more than $15 billion in payments.
-
Saniona moves depression drug closer to first-in-human trial
The Swedish-Danish research company Saniona has submitted an application to the FDA to begin testing its oral drug candidate in patients with major depressive disorder.
-
Danish health minister: Europe must act on China
Danish politicians and medtech industry representatives are calling for closer cooperation between hospitals and companies to boost innovation. Danish Health Minister Ida Auken also warns that Europe must act to keep pace with growing competition from China.
-
He helped build Oslo Cancer Cluster – now AI is his next challenge
After 12 years, Ketil Widerberg is stepping down as General Manager of Oslo Cancer Cluster. His next move takes him to Oslo University Hospital, where he will focus on artificial intelligence and healthcare.
-
How GLP-1 drugs are changing what we buy at the supermarket
In both Sweden and Denmark, grocery industry organisations are predicting billion-krona sales losses as the use of weight-loss drugs increases. So far, however, major supermarket chains say they have seen little sign of an impact.
-
Natural Cycles sharpens Nordic focus with new regional chief
After nearly a decade at Natural Cycles, Sofie Askervall has stepped into the newly created role of Head of Nordics. “Right now, we are looking closely at Norway,” she says.
-
Orexo seeks SEK 250 million to fund pipeline and DOJ settlement
Orexo had SEK 118.7 million in available cash at the end of August. The Uppsala-based company now wants to raise a further SEK 250 million to fund its development pipeline and the expected DOJ settlement.
-
Russian lab worker’s death sparks suspected plague investigation
Russian authorities have placed around 200 people under medical observation amid suspicions of plague, following the death of a 28-year-old laboratory worker in the Irkutsk region.
-
Sanofi strikes another multibillion-dollar deal – four candidates in focus
Sanofi and Regeneron are stepping up their long-standing partnership. The companies are now investing in four new antibody drugs in a deal that could be worth up to $8 billion.
-
Novo slashes Wegovy price in Sweden – “It makes sense”
Novo is cutting the price of its weight-loss drug Wegovy by 20 per cent in Sweden. According to the company, the move is not aimed at gaining market share, but at reducing the financial burden on patients and making treatment available to more people.
-
Study finds key gut bacterium undetectable in one in three Swedish infants
One in three Swedish infants have no detectable levels of a bacterium that helps support the developing immune system, according to a new Swedish study. The figure is notably high compared with similar studies from the UK and US.
-
Swedish obesity challenger halts drug programme
Swedish biotech company Empros Pharma is discontinuing its obesity drug programme. Difficulties in securing funding and growing competition from GLP-1 drugs are cited as the reasons.
-
Anna Törner: Time for new body ideals?
Why are perfectly healthy people turning to high-tech medicines to achieve outdated beauty ideals? Anna Törner asks in her latest column.
Get access to all content on Life Science Focus
No commitment or card information required
Already a subscriber? Log In
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement
Advertisement
Advertisement
BREAKING